Equities research analysts forecast that Minerva Surgical, Inc. (NASDAQ:UTRS – Get Rating) will announce ($0.33) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Minerva Surgical’s earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.36). The firm is scheduled to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Minerva Surgical will report full-year earnings of ($1.24) per share for the current financial year, with EPS estimates ranging from ($1.44) to ($1.13). For the next year, analysts anticipate that the company will post earnings of ($1.00) per share, with EPS estimates ranging from ($1.05) to ($0.92). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Minerva Surgical.
Minerva Surgical (NASDAQ:UTRS – Get Rating) last released its quarterly earnings data on Wednesday, May 11th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.07).
UTRS opened at $2.35 on Thursday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.72 and a current ratio of 2.32. The business has a 50 day moving average of $3.84 and a 200-day moving average of $5.21. Minerva Surgical has a 52 week low of $1.61 and a 52 week high of $10.37.
A number of large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in Minerva Surgical during the fourth quarter valued at $54,000. Renaissance Technologies LLC bought a new stake in shares of Minerva Surgical in the 4th quarter worth $78,000. BlackRock Inc. bought a new stake in shares of Minerva Surgical in the 4th quarter worth $88,000. Millennium Management LLC bought a new stake in shares of Minerva Surgical in the 4th quarter worth $134,000. Finally, Ghisallo Capital Management LLC bought a new stake in shares of Minerva Surgical in the 4th quarter worth $386,000. Institutional investors and hedge funds own 69.55% of the company’s stock.
Minerva Surgical Company Profile (Get Rating)
Minerva Surgical, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.
- Get a free copy of the StockNews.com research report on Minerva Surgical (UTRS)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.